Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor
Copyright 1998 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1998
To the Editor.— The article by Dr O'Leary
and colleagues1 has important clinical implications.
The results suggest that PAPNET-automated rescreening (Neuromedical Systems
Inc, Suffern, NY) has little clinical utility since the cost does not justify
the few incremental cases of cervical disease it may detect. This article
confirms what many epidemiologists, clinicians, and scientists have suspected
all along. Although the concept is sound, there is no automated rescreening
technology to date that can address the poor sensitivity and specificity of
the Papanicolaou (Pap) smear in cervical cancer screening.
Greenberg MD. Rescreening of Cervical Papanicolaou Smears Using PAPNET. JAMA. 1998;279(22):1785-1788. doi:10-1001/pubs.JAMA-ISSN-0098-7484-279-22-jac80008